Scientists probe immune cell secrets in healthy volunteers

NCT ID NCT00397280

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 02, 2026 · Updated 11 times

Summary

This study looks at how certain white blood cells (neutrophils and monocytes) sense signals in the body and what substances they release, especially when they might cause inflammation. Healthy adults aged 18 to 65 who weigh at least 110 pounds can join by donating blood up to six times a year. The goal is to better understand the body's natural immune responses, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 750 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2009

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Any healthy donors meeting inclusion/exclusion criteria

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: * Normal, healthy adult donors as judged by screening questionnaire * Nonpregnant * Weighing at least 110 lbs * 18-65 years of age * HIV negative (proof required every 6 months we will conduct test)\* * Hepatitis B surface antigen and hepatitis C serology negative (checked every 6 months we will conduct test)\* * The rationale for HIV and hepatitis viral testing is that chronic viral infection may alter and possibly invalidate our experimental results. HIV and hepatitis results will be confidentially obtained. Testing will be contracted to an external certified laboratory and will be paid for by the study group. Results will be available only to the study doctor/PI (Fessler), the study coordinator, the CRU Director (Garantziotis, LAI), and the donor, with the few caveats that follow All positive HIV, hepatitis B, and hepatitis C results will be promptly communicated to the donor by the study doctor/PI or the CRU Director. The participant will be referred to their physician and/or to the N.C. Department of Health for confirmatory testing and counseling. As explained in detail in the attached Supplement describing N.C. State Department of Health code will be followed. The state code mandates reporting of positive results along with the participant s name and identifying information to the N.C. Department of Public Health. Upon contracting with the testing laboratory, clarification will be obtained and documented as to whether the contracted laboratory or the study MD will be responsible for reporting positive results to the state to avoid duplication of reporting. Upon receipt of the test results, the N.C. Department of Health will contact the participant to inform them of the positive result, how to find care, how to avoid infecting others, how the newly diagnosed HIV and/or hepatitis infection is reported, and the importance of informing their partners at possible risk because of their HIV and/or hepatitis infection. If the HIV, hepatitis B, and hepatitis C results are negative, the participant will be not be notified. However, the participant may contact the research study nurse for their results. HIV and hepatitis B/C test results, non-reactive and reactive, will be documented confidentially by the PI or study coordinator in the subject s file, and kept in a locked file cabinet in the CRU Medical Records Room.In order to document the reporting procedure and the time associated with the reporting process, a document has been created and placed in the study specific manual (Hepatitis B/C and HIV Notification Process for Reactive Results Form) EXCLUSION CRITERIA: By questionnaire: Feeling ill within the last 24 hours. Alcohol consumption in the last 24 hours. Visit to the dentist in the last 24 hours. A doctor visit for illness or vaccination in the last 2 weeks. Diarrhea in the last 2 weeks. Recurrent fever (4 weeks). Pregnant or suspected pregnancy in the last 6 weeks. Blood or plasma donation that will cause the participant to exceed 550ml of blood in the last 8 weeks. Receiving a blood donation in the past 12 months. Bleeding disorder. Anemia. Heart problems. Insulin dependent diabetes. Problems with blood donation. Risk of or evidence of Creutzfeldt-Jacob Disease in the family. HIV-positive status, Hepatitis B/C-positive status or other confirmed or suspected immunosuppressive or immunodeficient conditions. Use of immunosuppressants or other immune-modifying drugs. Use of selected medications within the preceding 5 days unless the PI or AI receiving the samples states otherwise (NSAIDS/aspirin/tylenol, antidepressants, antihistamines , corticosteroids, HMG CoA reductase inhibitors, and antihypertensives). By exam: Temperature over 99.5 F. Blood pressure less than 90/50. Blood pressure higher than 170/95 mm Hg. Pulse rate less than 50 or greater than 100 beats/minute. If blood donation exceeds 200ml: * Hematocrit less than 34% for women or less than 36% for men, or greater than 56% for either gender. * Patients will be informed of disqualifying vital signs and hematocrit values and advised by trained staff, as appropriate, to seek assistance from their physician.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Inflammation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • NIEHS Clinical Research Unit (CRU)

    RECRUITING

    Research Triangle Park, North Carolina, 27709, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.